PRM Pharma
Private Company
Funding information not available
Overview
PRM Pharma is a specialty pharmaceutical company with a focused mission to develop and commercialize lower-dose versions of established drugs. The company leverages the FDA's 505(b)(2) pathway for efficient development, capitalizing on existing safety and efficacy data to bring optimized dosing to patients, particularly in hypertension and other therapeutic areas. Its first commercial product, HemiClor® (a low-dose hydrochlorothiazide), is now available in U.S. pharmacies, marking its transition to a commercial-stage entity. The leadership team, led by founder and CEO Joseph T. McDevitt, has a proven track record in low-dose drug development, having previously created the widely prescribed Microzide®.
Technology Platform
Strategic use of the FDA's 505(b)(2) regulatory pathway to develop and secure approval for new, lower-dose formulations of already-approved prescription drugs, leveraging existing safety and efficacy data to reduce development time and cost.
Opportunities
Risk Factors
Competitive Landscape
PRM Pharma competes in the crowded generic pharmaceutical market for established drugs like hydrochlorothiazide, as well as with other specialty pharma companies utilizing the 505(b)(2) pathway. Its primary differentiation is its singular focus on lower-dose optimization and the proven track record of its founder in successfully commercializing a prior low-dose product in the same class.